Novel players in cardioprotection: Insulin like growth factor-1, angiotensin-(1–7) and angiotensin-(1–9). (November 2015)

• Record Type: Journal Article
• Authors: Westermeier, Francisco; Bustamante, Mario; Pavez, Mario; García, Lorena; Chiong, Mario; Ocaranza, María Paz; Lavandero, Sergio
• Is Part Of: Pharmacological research. Volume 101(2015:Nov.)
• Page Start: 41
• Page End: 55
• Publication Date: 2015-11
• Subjects: AA arachidonic acid (AA) -- ACE angiotensin converting enzyme -- ACE 2 angiotensin converting enzyme 2 -- AMPK AMP-activated protein kinase -- Ang I angiotensin I -- Ang II angiotensin II -- Ang-(1–7) angiotensin-(1–7) -- Ang-(1–9) angiotensin (1–9) -- ARB angiotensin receptor blockers -- AT1R angiotensin type 1 receptor -- AT2R angiotensin type 2 receptor -- ATIP1 AT2R-interacting protein 1 -- BP blood pressure -- CHD coronary heart disease -- CV cardiovascular -- CVD cardiovascular diseases -- DUSP-1 dual-specificity phosphatase-1 -- eNOS endothelial nitric oxide synthase -- ERK extracellular-regulated kinase -- GH growth hormone -- GPCR G-protein coupled receptor -- HF heart failure -- HT hypertension -- IGF-1 insulin-like growth factor-1 -- IGF-1R IGF-1 receptor -- IGFBPs IGF binding proteins -- IGFD IGF-1 deficiency -- IκB inhibitor of NF-κB -- InsP3 inositol 1, 4, 5-triphosphate -- IR insulin receptor -- IRS-1 IR substrate-1 -- MasR Mas receptor -- MI myocardial infarction -- mTOR mechanistic target of rapamycin -- NO nitric oxide -- PI3K phosphatidyl inositol-3 kinase, PLA2, phospholipase A2 -- PLC phospholipase C -- PTP protein tyrosine phosphatase -- RAS renin-angiotensin system -- rhIGF-1 recombinant human IGF-1 -- ROS reactive oxygen species -- SERCA2 sarco(endo)plasmic reticulum Ca2+ ATPase 2 -- STZ streptozotocin -- VSMC vascular smooth muscle cells; Cardioprotection -- Growth factor -- Renin-angiotensin system -- Cardiovascular diseases -- Insulin-like growth factor-1 -- Angiotensin-(1–7) -- Angiotensin-(1–9); Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2015.06.018
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Insulin-like growth factor-1, angiotensin-(1–7) and angiotensin-(1–9) have been proposed to be important mediators in cardioprotection. A large body of evidence indicates that insulin like growth factor-1 has pleotropic actions in the heart (i.e., contractility, metabolism, hypertrophy, autophagy, senescence and cell death) and, conversely, its deficiency is associated with impaired cardiac function. Recently, we reported that insulin like growth factor-1 receptor is also located in plasma membrane invaginations with perinuclear localization, highlighting the role of nuclear Ca 2+ signaling in the heart. In parallel, angiotensin-(1–7) and angiotensin (1–9) acting through Mas receptor and angiotensin type 2 receptor have emerged as a novel anti-hypertensive molecules promoting vasodilatation and preventing heart hypertrophy. In this review we discuss the scientific evidence available regarding insulin-like growth factor-1, angiotensin-(1–7) and angiotensin-(1–9) in cardioprotection and its potential application as novel therapeutic targets for treating cardiac diseases.